Exactech Inc (EXAC) 25.42 $EXAC Exactech Has Returned

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 7:03 PM

Exactech Inc (EXAC) 25.42 $EXAC

Exactech Has Returned 26.6% Since SmarTrend Recommendation (EXAC)
Comtex SmarTrend(R) - Fri Jun 10, 1:24PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 26.59% as of today's recent price of $25.33.
EXAC: 25.42 (+0.12)

DENTSPLY (XRAY) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 6:02AM CDT
Shares of DENTSPLY International Inc. (XRAY) rallied to a new 52-week high of $64.59 on Jun 9.
IRMD: 21.35 (-0.13), MASI: 52.10 (-0.32), EXAC: 25.42 (+0.12), XRAY: 63.61 (-0.82)

TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 3:37AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations.
IRMD: 21.35 (-0.13), MASI: 52.10 (-0.32), TROV: 4.28 (-0.60), EXAC: 25.42 (+0.12)

Exactech and University of Florida Expand Partnership, Promote Health Education with Naming of "Exactech Arena" at the Stephen C. O'Connell Center
BusinessWire - Thu Jun 09, 3:59PM CDT
Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, announced today an expansion of its long-standing partnership with the University of Florida (UF) through naming of Exactech Arena at the newly remodeled Stephen C. O'Connell Center, a sports and entertainment complex on the university's campus.
EXAC: 25.42 (+0.12)

TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:39AM CDT
TrovaGene Inc. (TROV) recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations in the urine of patients with non-small cell lung cancer (NSCLC).
IRMD: 21.35 (-0.13), MASI: 52.10 (-0.32), TROV: 4.28 (-0.60), EXAC: 25.42 (+0.12)

Natus Medical Expands Share Repurchase Program by $20M
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:54AM CDT
Natus Medical Inc. (BABY) recently announced an expansion of its share repurchase program, which authorizes it to buy back additional shares worth $20 million by Jun 1, 2017.
BABY: 36.39 (-0.32), MASI: 52.10 (-0.32), EXAC: 25.42 (+0.12), CRY: 11.88 (-0.10)

Exactech Up 24.9% Since SmarTrend Uptrend Call (EXAC)
Comtex SmarTrend(R) - Fri Jun 03, 1:04AM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 24.89% as of today's recent price of $24.99.
EXAC: 25.42 (+0.12)

Inogen (INGN) Introduces Next-Gen Inogen One G4 POC
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:15AM CDT
Inogen Inc (INGN) recently launched a next-generation portable oxygen concentrator (POC) -- Inogen One G4.
MASI: 52.10 (-0.32), INGN: 49.46 (-0.77), EXAC: 25.42 (+0.12), CRY: 11.88 (-0.10)

Shares of EXAC Up 21.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 26, 1:34PM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 21.24% as of today's recent price of $24.26.
EXAC: 25.42 (+0.12)

Cynosure (CYNO) Up on FDA Approval for New 1064nm LDS
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:44AM CDT
Cynosure Inc. (CYNO) recently announced the receipt of FDA approval for marketing a new Laser Delivery System (LDS) for PicoSure.
IRMD: 21.35 (-0.13), MASI: 52.10 (-0.32), CYNO: 51.02 (-1.06), EXAC: 25.42 (+0.12)

22.3% Return Seen to Date on SmarTrend Exactech Call (EXAC)
Comtex SmarTrend(R) - Thu May 19, 1:28AM CDT
SmarTrend identified an Uptrend for Exactech (NASDAQ:EXAC) on April 1st, 2016 at $20.01. In approximately 2 months, Exactech has returned 22.29% as of today's recent price of $24.47.
EXAC: 25.42 (+0.12)

TrovaGene (TROV) Q1 Loss Wider than Expected, Stock Gains
Zacks Equity Research - Zacks Investment Research - Wed May 11, 7:16AM CDT
TrovaGene Inc (TROV) reported adjusted loss of 36 cents per share in the first quarter of 2016, wider than the year-ago loss of 33 cents.
TROV: 4.28 (-0.60), TECH: 113.08 (-0.74), EXAC: 25.42 (+0.12), NVRO: 72.83 (-2.89)

Exactech Inc. (Nasdaq: EXAC) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Mon May 02, 9:00AM CDT
What:
EXAC: 25.42 (+0.12), NDAQ: 65.58 (-0.08)

Exactech Celebrates 20-Year Nasdaq Listing Anniversary
BusinessWire - Mon May 02, 8:00AM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, announced today that in honor of the company's 20th anniversary of its Nasdaq listing, Exactech founders Bill Petty, MD, Betty Petty and Gary Miller, PhD, will ring the Nasdaq Closing Bell on Tuesday, May 3. The ceremony will take place from 3:45 - 4:00 p.m. ET at Nasdaq MarketSite in Times Square, New York.
EXAC: 25.42 (+0.12)

DexCom (DXCM) Q1 Loss Wider than Expected, Stock Down
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:46AM CDT
Shares of DexCom Inc. (DXCM) fell 3.6% to close at $65.96 on Apr 28, following a disappointing first-quarter 2016 earnings release.
ANTM: 131.52 (-2.23), DXCM: 71.91 (-0.76), INGN: 49.46 (-0.77), EXAC: 25.42 (+0.12)

Varian (VAR) Beats Q2 Earnings by a Penny, Lags Revenues
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:19AM CDT
Varian Medical Systems Inc. (VAR) reported earnings of $1.09 per share in the second quarter of fiscal 2016, which beat the Zacks Consensus Estimate by a penny.
RTIX: 3.71 (unch), VAR: 85.30 (-0.27), INGN: 49.46 (-0.77), EXAC: 25.42 (+0.12)

Accuray (ARAY) Posts Earnings in Q3, Down on View Cut
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:55AM CDT
Shares of Accuray Inc. (ARAY) fell 3.3% in after-hours trading following the company's third-quarter fiscal 2016 results and trimmed fiscal 2016 guidance.
INGN: 49.46 (-0.77), EXAC: 25.42 (+0.12), ARAY: 5.30 (-0.30), HOLX: 34.14 (-0.81)

Exactech posts 1Q profit
Automated Insights - Tue Apr 26, 4:07PM CDT
GAINSVILLE, Fla. (AP) _ Exactech Inc. (EXAC) on Tuesday reported first-quarter net income of $4.4 million.
EXAC: 25.42 (+0.12)

Exactech Receives FDA 510(k) Clearance for Vantage(TM) Total Ankle
BusinessWire - Mon Apr 25, 8:20AM CDT
Exactech Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for extremities, knee, hip, spine and biologic materials, announced today it has received clearance from the U.S. Food and Drug Administration to market the Vantage(TM) Total Ankle to treat patients who suffer from arthritis in the ankle. The Vantage Total Ankle is the latest product in the company's extremities line, and its first in the foot and ankle market.
EXAC: 25.42 (+0.12)

Pacific Biosciences (PACB) Q1 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 7:21AM CDT
Pacific Biosciences of California Inc. (PACB) reported a decent first-quarter 2016, thanks to the growing demand for its new Sequel system.
PACB: 9.56 (-0.24), GMED: 24.63 (-0.54), INGN: 49.46 (-0.77), EXAC: 25.42 (+0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Durability Over Comfort: Vibram's Global Footwear Shift

Durability Takes Center Stage in Footwear Choices Out with the fleeting, in with the durable! Vibram, that powerhouse in performance soles known for its little yellow octagon logo, is grabbing durability by the laces and pushing it to the forefront of the footwear game. With a freshly minted global survey shaking things up, turns out almost 8 in 10 of us aren't just...

HONOR2U Celebrates Veterans' Transition to Public Safety

Veterans Day Reflections Beyond the Battlefield You can hang up the uniform, but you can't hang up the call of duty. This Veterans Day, HONOR2U salutes those stepping off the battlefield right into our communities—trading military fatigues for public safety gear. They've swapped one uniform for another, and it's not just about new fibers; it's about carrying the torch...

Hexnode XDR Expands Threat Detection, MacOS Support

Hexnode XDR: A Game Changer for MacOS Threats Ever heard of Hexnode? Well, today's chat is all about them beefing up their XDR platform. They’ve sagely added support for macOS—finally given the platform some love alongside Windows. It's about time! This move is a big win for everyone whose daily grind depends on keeping threats at bay across platforms. We’re talking...

Decoding Renters vs. Homeowners Insurance Needs

Breaking Down Policy Differences If you've ever scratched your head over the insurance landscape, join the club. Renters and homeowners insurance each serve a specific role on the financial protection battlefield, and knowing what you're signing up for is downright vital. Oscar Salas from HelloNation lays out the core differences for anyone wise enough to get their heads...

Azenta's 2026 Gains Mask Deeper Challenges Ahead

Azenta's Financial Tangle in Fiscal 2026 You ever feel those moments when the numbers paint a pretty picture, but your gut knows there's more beneath? That's Azenta, Inc. (Nasdaq: AZTA) for fiscal 2026. We’re gazing at a revenue uplift of 5% year over year, hitting $622 million from continuing operations. Great, right? But dig deeper, and the tale isn't all sunshine and...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Leech Tishman Bolsters Entertainment Group with Key Hires

In the legal world, adding a couple of seasoned litigation heavyweights to a practice is akin to fortifying your castle before a siege. Leech Tishman, a national law firm, has just done that by bringing Bryan M. Sullivan and Zachary C. Hansen aboard to bolster their Entertainment & Sports Industry Group. With these additions, they're not just shoring up their defenses;...

Call for Biotech Shift: Scarcity Drives Urgency

The Cry for an Industrial Biotech Shift Alright, folks, here's the deal: James Michael Matthew is waving a red flag. He's saying it's time to overhaul our approach to industrial biotechnology. Why? Because we're up against some big-time raw material shortages. Matthew's call isn't just a whisper in the wind; it's a siren echoing through an industry teetering on the edge...

Sound Credit Union, WTA Team Up for Trail Support

Heading Into the Great Outdoors with Every Swipe You ever feel like your money's going nowhere useful? Well, folks in Washington are about to flip the script thanks to Sound Credit Union and the Washington Trails Association (WTA). They've cooked up a slick new money move—a co-branded debit and credit card program—where every swipe backs the state's beloved trails. A...